Ingen Technologies, Inc. (Pink Sheets:IGNT), an emerging medical device manufacturer developing innovative solutions for the respiratory market, with a new patented and proprietary medical product line targeting the $8B respiratory market, announced today that the company revenues have increased from $10,401 reported in May 31, 2009, to $128,917 ending May 31, 2010. This is an increase of 1,139%.
The company will release its annual report next week, while it finalizes the audited restatements later this month as part of our return as a fully reporting company. Ingen delisted on December 4, 2008, at the cusp of the global recession, in order to file a Reg-D Registration and continue funding its product development and sales program. Although at the time it was a difficult decision to be made by management, it turned out to be a wise decision. The company was able to fund its ISO Certification, product inventory requirements, advertising campaign and government contract program.
"Our hard work and perseverance is beginning to show some results," said Scott Sand, CEO. Sand further stated, "The annual report will be published next week. Our cash reserves are steady, our sales are increasing, we've paid off the majority of our debt and shareholder support is strong. After the annual report is released I plan to make a public statement regarding the future growth of Ingen."
Antibiotics ineffective for cough treatment in lower respiratory tract infections